Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
11
Today In Oncology
FDA Approves Pimicotinib for Symptomatic TGCT
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Extended Follow-up of Nivolumab Ipilimumab for Localized dMMR MSI-H Gastric GEJ Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo